Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s738, 2026. DOI: 10.25251/0bwr4a20. Disponível em: https://skin.dermsquared.com/skin/article/view/4061. Acesso em: 2 may. 2026.